Volume 7 Supplement 1

2013 WAO Symposium on Immunotherapy and Biologics

Open Access

Poster 2004: Bio Immun(G)En medicine or how to link scientific research and daily therapeutic practice

  • Gilbert Glady1
World Allergy Organization Journal20147(Suppl 1):P20

DOI: 10.1186/1939-4551-7-S1-P20

Published: 3 February 2014

Background

The main object of our particular approach in Bio Immune(G)enetic Medicine, is to use the reaction models specific to the human immune system, for the purpose of not only diagnosis but also - and more especially –therapy. In this respect it resembles theranostic nanomedicine.

Methods

To reach diagnosis we use a wide range of biological parameters such as lymphocyte typing and protein profiles as well as many bacterial and viral serologies, but also biomarkers such as thymidine-kinase or transketolase-1. Indeed, taken together, these factors enable us, on the one hand to substantiate a precise and relevant biological diagnosis, and on the other to obtain a guide for suitable subsequent therapy.

The therapy uses numerous immune-competent molecules, in particular microRNAs, which are involved in one of the principal epigenetic processes currently known. They are prepared according to the homeopathic dilution-dynamisation mode, this being the sole means of ensuring total safety in terms of any adverse side-effects for the patient, and therapeutic effectiveness is based on the universal today well-known principle of Hormesis.

Results

This approach enables the development of a bio-mimetic immune therapy, the medium-to-long-term regulatory effects of which, are proving to be extremely beneficial to patients in a large number of immuno-dependent diseases.

Conclusions

The description of various clinical cases will demonstrate this innovative method and provide a clear example of how discoveries in the field of basic research can be applied directly in the domain of clinical and therapeutic medicine by humans.

Authors’ Affiliations

(1)
EBMA

Copyright

© Glady; licensee BioMed Central Ltd. 2014

This article is published under license to BioMed Central Ltd. This is an Open Access article distributed under the terms of the Creative Commons Attribution License (http://creativecommons.org/licenses/by/2.0), which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited. The Creative Commons Public Domain Dedication waiver (http://creativecommons.org/publicdomain/zero/1.0/) applies to the data made available in this article, unless otherwise stated.

Advertisement